97 related articles for article (PubMed ID: 8568590)
1. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type.
Ariza A; Mate JL; Isamat M; López D; Von Uexküll-Güldeband C; Rosell R; Fernández-Vasalo A; Navas-Palacios JJ
J Pathol; 1995 Dec; 177(4):363-8. PubMed ID: 8568590
[TBL] [Abstract][Full Text] [Related]
2. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
3. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer.
Miyoshi T; Kondo K; Hino N; Uyama T; Monden Y
Clin Cancer Res; 1997 Aug; 3(8):1289-97. PubMed ID: 9815811
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
6. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
8. [Expression of standard and variant CD44 in human lung cancer].
Zhao H; Fang J; Du G
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep; 21(9):541-3. PubMed ID: 11360506
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 in primary lung carcinomas using histological and cytological analyses.
Shimbori M; Kijima H; Sato S; Yoshida H; Sato T; Terasaki-Fukuzawa Y; Onoda N; Kanabuchi K; Abe Y; Nakamura M; Hattori M; Ohno E; Kuramoto H
Anticancer Res; 2003; 23(1A):115-21. PubMed ID: 12680202
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.
Ashida K; Terada T; Kitamura Y; Kaibara N
Hepatology; 1998 Apr; 27(4):974-82. PubMed ID: 9537436
[TBL] [Abstract][Full Text] [Related]
11. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines.
Teder P; Bergh J; Heldin P
Cancer Res; 1995 Sep; 55(17):3908-14. PubMed ID: 7543820
[TBL] [Abstract][Full Text] [Related]
12. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
14. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression.
Li H; Guo L; Li JW; Liu N; Qi R; Liu J
Int J Oncol; 2000 Nov; 17(5):927-32. PubMed ID: 11029494
[TBL] [Abstract][Full Text] [Related]
15. Are CD44 variant isoforms involved in human tumour progression?
Günthert U; Stauder R; Mayer B; Terpe HJ; Finke L; Friedrichs K
Cancer Surv; 1995; 24():19-42. PubMed ID: 7553660
[TBL] [Abstract][Full Text] [Related]
16. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression.
Lu D; Tawfik O; Pantazis C; Hobart W; Chapman J; Iczkowski K
Gynecol Oncol; 1999 Oct; 75(1):84-90. PubMed ID: 10502431
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter.
Masuda M; Takano Y; Iki M; Makiyama K; Noguchi S; Hosaka M
J Urol; 1999 Mar; 161(3):805-8; discussion 808-9. PubMed ID: 10022688
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
20. CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma.
Lee LN; Kuo SH; Lee YC; Chang YL; Chang HC; Jan IS; Yang PC
J Formos Med Assoc; 2005 Aug; 104(8):541-8. PubMed ID: 16193174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
